Oncology
Adult Acute Myeloid Leukemia
11
Pipeline Programs↗
3
Active Trials↗
8
Companies Involved↗
Adult Acute Myeloid Leukemia is an emerging landscape with 11 programs across 8 companies. The most active players are Magenta Therapeutics, Inc., Karyopharm Therapeutics Inc, Karuna Therapeutics, Inc., a Bristol Myers Squibb company. 4 therapies are approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 22
Phase 32
Analysis
Trial Status
11
clinical trials
Completed4 · 36%
Unknown status2 · 18%
Recruiting2 · 18%
Terminated1 · 9%
Withdrawn1 · 9%
Active, not recruiting1 · 9%
Clinical Trials
Trial Activity
11 trials
Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia
Active, not recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2/3·NCT05356169·312 enrolled
Risk-adapted Therapy for Adult Acute Myeloid Leukemia.
Completed·GGrupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias·Phase 2·NCT01716793·354 enrolled
Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years
Unknown status·—·N/A·NCT02432872·300 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)